Effects of an angiotensin receptor antagonist candesartan versus a calcium channel blocker amlodipine on microvascular rarefaction endothelial dysfunction and microalbuminuria in essential hypertension.

Trial Profile

Effects of an angiotensin receptor antagonist candesartan versus a calcium channel blocker amlodipine on microvascular rarefaction endothelial dysfunction and microalbuminuria in essential hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Candesartan cilexetil (Primary) ; Amlodipine
  • Indications Essential hypertension
  • Focus Pharmacodynamics
  • Acronyms CAMIRA
  • Most Recent Events

    • 20 Aug 2014 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record.
    • 25 Jan 2014 Accrual to date is 45% according to United Kingdom Clinical Research Network.
    • 24 Oct 2013 Accrual to date is 43% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top